Posted by Michael Wonder on 28 Apr 2021
H.R. 3’s international reference pricing misses the mark
28 April 2021 - The White House and Congress have declared that reining in Medicare prescription drug costs to help older adults and people with disabilities is a top priority.
But one drug pricing strategy on the table would have an outsized negative impact on people with Alzheimer’s disease and decimate research trying to find effective treatments for it.
